Logo

Takara Pays Lynx $3M in Modification of Licensing Agreement

Aug 05, 2003

NEW YORK, Aug. 5 (GenomeWeb News) - Lynx Therapeutics of Hayward, Calif., said today that Takara Bio of Japan has paid it $3 million in a modification of the two companies' technology licensing agreement.

 

Under the modification of the agreement, which was originally signed in 2000 and expanded earlier this year, Takara will now have the exclusive, royalty-free right to use Lynx's technologies in China, Korea, and Japan.

 

Takara will also be relieved of its obligation to pay Lynx, $2 million in 2003 and 2004, along with royalties, and has obtained three of Lynx' Massively Parallel Signature Sequencing, or MPSS, instruments, in addition to the two it already owns.

 

The modified agreement also relieves Takara, which owns 13.5 percent of Lynx outstanding common stock, of an obligation under the original agreement to make additional equity investments in Lynx.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.